- Home
- BIIB
BIIB
Biogen Inc.
as 04-25-2025 4:00pm EST
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as Biogen Inc. BIIB prepares to release earnings report on 01 May 2025.
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 19.9B | IPO Year: | 1991 |
| Target Price: | $218.29 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 28 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.18 | EPS Growth: | 40.28 |
| 52 Week Low/High: | $110.04 - $238.00 | Next Earning Date: | 05-01-2025 |
| Revenue: | $9,675,900,000 | Revenue Growth: | -1.62% |
| Revenue Growth (this year): | -2.78% | Revenue Growth (next year): | -0.78% |
Stock Insider Trading Activity of Biogen Inc. (BIIB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SHERWIN STEPHEN A | BIIB | Director | Mar 7 '25 | Sell | $150.02 | 8,760 | $1,314,141.91 | 11,318 |
Latest Biogen Inc. News
BIIB Breaking Stock News: Dive into BIIB Ticker-Specific Updates for Smart Investing
MT Newswires
19 hours ago
RBC Cuts Price Target on Biogen to $217 From $225, Keeps Outperform Rating
Zacks
2 days ago
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
StockStory
2 days ago
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
Zacks
2 days ago
Can Biogen Keep the Beat Streak Alive This Earnings Season?
Pharmaceutical Technology
2 days ago
Biogen’s Friedreich’s ataxia treatment authorised in UK
MT Newswires
3 days ago
Goldman Sachs Adjusts Price Target on Biogen to $197 From $219, Maintains Buy Rating
MT Newswires
4 days ago
RBC Lifts Price Target on Biogen to $225 From $221, Keeps Outperform Rating
MT Newswires
9 days ago
BMO Capital Adjusts Biogen Price Target to $128 From $139
Compare BIIB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIIB Biogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.